Patents by Inventor Alexander Mayweg

Alexander Mayweg has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Modified IL-2 polypeptides and uses thereof
    Patent number: 11633488
    Abstract: The present disclosure relates to modified IL-2 polypeptides, compositions comprising modified IL-2 polypeptides, methods of making the same, and methods of using the modified IL-2 polypeptides for treatment of diseases. In one aspect, the disclosure relates to the treatment of cancer using the modified IL-2 polypeptides. In some embodiments, the disclosed IL-2 polypeptides exhibit preferential binding characteristics to IL-2 receptor ?? complex (IL-2R?) over IL-2 receptor ??? complex (IL-2R?). In some embodiments, the molecular weight distribution of the modified IL-2 polypeptides is monodispersed.
    Type: Grant
    Filed: January 8, 2021
    Date of Patent: April 25, 2023
    Assignee: Bright Peak Therapeutics AG
    Inventors: Vijaya Raghavan Pattabiraman, Roberto Iacone, Jean-Philippe Carralot, Matilde Arévalo-Ruiz, Jeffrey William Bode, Alexander Mayweg, Fränzi Weibel, Anna Haydn, Régis Boehringer, Görkem Kurtuldu Sahin, Claudia Fetz, Camille Delon, Eric Armentani, Alexander Flohr, Giorgio Ottaviani
  • TYROSINE KINASE INHIBITOR COMPOSITIONS, METHODS OF MAKING AND METHODS OF USE
    Publication number: 20220363666
    Abstract: The present disclosure relates to new compounds or pharmaceutically acceptable salts or stereoisomers thereof of formula I as inhibitors of receptor tyrosine kinases (RTK), in particular extracellular mutants of ErbB-receptors. The present disclosure also relates to methods of preparation these compounds, compositions comprising these compounds, and methods of using them in the treatment of cancer in mammals (e.g. humans).
    Type: Application
    Filed: March 12, 2021
    Publication date: November 17, 2022
    Applicant: Black Diamond Therapeutics, Inc.
    Inventors: Alexander FLOHR, Alexander MAYWEG, George TRAINOR, David M. EPSTEIN, Matthew O'CONNOR, Elizabeth BUCK, Luca ARISTA
  • TYROSINE KINASE INHIBITOR COMPOSITIONS, METHODS OF MAKING AND METHODS OF USE
    Publication number: 20220041613
    Abstract: The present disclosure relates to new compounds of formula I and pharmaceutically acceptable salts and stereoisomers thereof, as inhibitors of receptor tyrosine kinases (RTK), in particular extracellular mutants of ErbB-receptors. The disclosure also relates to methods of preparation these compounds, compositions comprising these compounds, and methods of using them in the treatment of abnormal cell growth in mammals, (e.g., humans).
    Type: Application
    Filed: September 24, 2019
    Publication date: February 10, 2022
    Inventors: Alexander FLOHR, Alexander MAYWEG, George TRAINOR, David M. EPSTEIN, Matthew O'CONNOR, Elizabeth BUCK
  • MODIFIED IL-2 POLYPEPTIDES AND USES THEREOF
    Publication number: 20210252157
    Abstract: The present disclosure relates to modified IL-2 polypeptides, compositions comprising modified IL-2 polypeptides, methods of making the same, and methods of using the modified IL-2 polypeptides for treatment of diseases. In one aspect, the disclosure relates to the treatment of cancer using the modified IL-2 polypeptides. In some embodiments, the disclosed IL-2 polypeptides exhibit preferential binding characteristics to IL-2 receptor ?? complex (IL-2R?) over IL-2 receptor ??? complex (IL-2R?). In some embodiments, the molecular weight distribution of the modified IL-2 polypeptides is monodispersed.
    Type: Application
    Filed: January 8, 2021
    Publication date: August 19, 2021
    Inventors: Vijaya Raghavan PATTABIRAMAN, Roberto IACONE, Jean-Philippe CARRALOT, Matilde ARÉVALO-RUIZ, Jeffrey William BODE, Alexander MAYWEG, Fränzi WEIBEL, Anna HAYDN, Régis BOEHRINGER, Görkem KURTULDU SAHIN, Claudia FETZ, Camille DELON, Eric ARMENTANI, Alexander FLOHR, Giorgio OTTAVIANI
  • Tyrosine kinase inhibitor compositions, methods of making and methods of use
    Patent number: 11034672
    Abstract: The present disclosure relates to new compounds or pharmaceutically acceptable salts or stereoisomers thereof of formula I as inhibitors of receptor tyrosine kinases (RTK), in particular extracellular mutants of ErbB-receptors. The present disclosure also relates to methods of preparation these compounds, compositions comprising these compounds, and methods of using them in the treatment of cancer in mammals (e.g. humans).
    Type: Grant
    Filed: April 17, 2020
    Date of Patent: June 15, 2021
    Assignee: Black Diamond Therapeutics, Inc.
    Inventors: Alexander Flohr, Alexander Mayweg, George Trainor, David M. Epstein, Matthew O'Connor, Elizabeth Buck, Luca Arista
  • TYROSINE KINASE INHIBITOR COMPOSITIONS, METHODS OF MAKING AND METHODS OF USE
    Publication number: 20210163447
    Abstract: The present disclosure relates to new compounds or pharmaceutically acceptable salts or stereoisomers thereof of formula I as inhibitors of receptor tyrosine kinases (RTK), in particular extracellular mutants of ErbB-receptors. The present disclosure also relates to methods of preparation these compounds, compositions comprising these compounds, and methods of using them in the treatment of cancer in mammals (e.g. humans).
    Type: Application
    Filed: April 17, 2020
    Publication date: June 3, 2021
    Inventors: Alexander FLOHR, Alexander MAYWEG, George TRAINOR, David M. EPSTEIN, Matthew O'CONNOR, Elizabeth BUCK, Luca ARISTA
  • Spirodiamine derivatives as aldosterone synthase inhibitors
    Patent number: 10035804
    Abstract: The invention provides novel compounds having the general formula (I) wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, R12, R13, R14, R5, A1, A2, m, n and p are as described herein, compositions including the compounds and methods of using the compounds.
    Type: Grant
    Filed: April 5, 2017
    Date of Patent: July 31, 2018
    Assignee: Hoffman-La Roche Inc.
    Inventors: Johannes Aebi, Kurt E. Amrein, Junli Chen, Benoit Hornsperger, Bernd Kuhn, Yongfu Liu, Dongbo Li, Hans Peter Maerki, Rainer E. Martin, Alexander Mayweg, Xuefei Tan, Jun Wu, Jianhua Yu
  • SPIRODIAMINE DERIVATIVES AS ALDOSTERONE SYNTHASE INHIBITORS
    Publication number: 20170204107
    Abstract: The invention provides novel compounds having the general formula (I) wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, R12, R13, R14, R5, A1, A2, m, n and p are as described herein, compositions including the compounds and methods of using the compounds.
    Type: Application
    Filed: April 5, 2017
    Publication date: July 20, 2017
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Johannes Aebi, Kurt E. Amrein, Junli Chen, Benoit Hornsperger, Bernd Kuhn, Yongfu Liu, Dongbo Li, Hans Peter Maerki, Rainer E. Martin, Alexander Mayweg, Xuefei Tan, Jun Wu, Jianhua Yu
  • 3,4-dihydro-2H-isoquinoline-1-one and 2,3-dihydro-isoindol-1-one compounds
    Patent number: 9695151
    Abstract: The invention provides novel compounds having the general formula (I) wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, R12, R13, R14, R15, A, m, n and p are as described herein, compositions including the compounds and methods of using the compounds.
    Type: Grant
    Filed: November 20, 2015
    Date of Patent: July 4, 2017
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Johannes Aebi, Kurt Amrein, Wenming Chen, Benoit Hornsperger, Bernd Kuhn, Yongfu Liu, Hans P. Maerki, Rainer E. Martin, Alexander Mayweg, Xuefei Tan, Lisha Wang, Mingwei Zhou
  • 3,4-dihydro-2H-isoquinoline-1-one and 2,3-dihydro-isoindol-1-one compounds
    Patent number: 9695152
    Abstract: The invention provides novel compounds having the general formula (I) wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, R12, R13, R14, R15, A, m, n and p are as described herein, compositions including the compounds and methods of using the compounds.
    Type: Grant
    Filed: November 20, 2015
    Date of Patent: July 4, 2017
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Johannes Aebi, Kurt Amrein, Wenming Chen, Benoit Hornsperger, Bernd Kuhn, Yongfu Liu, Hans P. Maerki, Rainer E. Martin, Alexander Mayweg, Xuefei Tan, Lisha Wang, Mingwei Zhou
  • 3,4-dihydro-2H-isoquinoline-1-one and 2,3-dihydro-isoindol-1-one compounds
    Patent number: 9505742
    Abstract: The invention provides novel compounds having the general formula (I) wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, R12, R13, R14, A, B, m, n and p are as described herein, compositions including the compounds and methods of using the compounds.
    Type: Grant
    Filed: November 20, 2015
    Date of Patent: November 29, 2016
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Johannes Aebi, Kurt Amrein, Wenming Chen, Benoit Hornsperger, Bernd Kuhn, Dongbo Li, Yongfu Liu, Hans P. Maerki, Rainer E. Martin, Alexander Mayweg, Xuefei Tan, Lisha Wang, Jun Wu, Mingwei Zhou
  • NEW 3,4-DIHYDRO-2H-ISOQUINOLINE-1-ONE AND 2,3-DIHYDRO-ISOINDOL-1-ONE COMPOUNDS
    Publication number: 20160075687
    Abstract: The invention provides novel compounds having the general formula (I) wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, R12, R13, R14, R15, A, m, n and p are as described herein, compositions including the compounds and methods of using the compounds.
    Type: Application
    Filed: November 20, 2015
    Publication date: March 17, 2016
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Johannes Aebi, Kurt Amrein, Wenming Chen, Benoit Hornsperger, Bernd Kuhn, Yongfu Liu, Hans P. Maerki, Rainer E. Martin, Alexander Mayweg, Xuefei Tan, Lisha Wang, Mingwei Zhou
  • NEW 3,4-DIHYDRO-2H-ISOQUINOLINE-1-ONE AND 2,3-DIHYDRO-ISOINDOL-1-ONE COMPOUNDS
    Publication number: 20160075686
    Abstract: The invention provides novel compounds having the general formula (I) wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, R12, R13, R14, A, B, m, n and p are as described herein, compositions including the compounds and methods of using the compounds.
    Type: Application
    Filed: November 20, 2015
    Publication date: March 17, 2016
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Johannes Aebi, Kurt Amrein, Wenming Chen, Benoit Hornsperger, Bernd Kuhn, Dongbo Li, Yongfu Liu, Hans P. Maerki, Rainer E. Martin, Alexander Mayweg, Xuefei Tan, Lisha Wang, Jun Wu, Mingwei Zhou
  • NEW 3,4-DIHYDRO-2H-ISOQUINOLINE-1-ONE AND 2,3-DIHYDRO-ISOINDOL-1-ONE COMPOUNDS
    Publication number: 20160075688
    Abstract: The invention provides novel compounds having the general formula (I) wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, R12, R13, R14, R15, A, m, n and p are as described herein, compositions including the compounds and methods of using the compounds.
    Type: Application
    Filed: November 20, 2015
    Publication date: March 17, 2016
    Applicant: HOFFMANN-LA ROCHE INC.
    Inventors: Johannes Aebi, Kurt Amrein, Wenming Chen, Benoit Hornsperger, Bernd Kuhn, Yongfu Liu, Hans P. Maerki, Rainer E. Martin, Alexander Mayweg, Xuefei Tan, Lisha Wang, Mingwei Zhou
  • 5-aryl pyridines as 11-beta inhibitors for the treatment of diabetes
    Patent number: 8211913
    Abstract: Compounds of formula (I): as well as pharmaceutically acceptable salts and esters thereof used in the form of pharmaceutical compositions.
    Type: Grant
    Filed: February 17, 2009
    Date of Patent: July 3, 2012
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Kurt Amrein, Daniel Hunziker, Bernd Kuhn, Alexander Mayweg, Werner Neidhart
  • Pyrazolones as inhibitors of 11?-hydroxysteroid dehydrogenase
    Patent number: 7622492
    Abstract: Provided herein are compounds of the formula (I): as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of diseases such as, for example, type II diabetes mellitus and metabolic syndrome.
    Type: Grant
    Filed: August 18, 2006
    Date of Patent: November 24, 2009
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Bruce Lester Banner, Joseph Anthony Bilotta, Nader Fotouhi, Paul Gillespie, Robert Alan Goodnow, Jr., Matthew Michael Hamilton, Nancy-Ellen Haynes, Agnieszka Kowalczyk, Alexander Mayweg, Michael Paul Myers, Sherrie Lynn Pietranico-Cole, Nathan Robert Scott, Kshitij Chhabilbhai Thakkar, Jefferson Wright Tilley, Kevin Richard Guertin
  • CB 1 receptor inverse agonists
    Patent number: 7579369
    Abstract: The present invention relates to compounds of formula (I) wherein R1, R2, R3, R4, R5, R6, m and X are as defined in the description and claims, and pharmaceutically acceptable salts thereof. The compounds are useful for the treatment and/or prophylaxis of diseases which are associated with the modulation of CB1 receptors.
    Type: Grant
    Filed: May 10, 2007
    Date of Patent: August 25, 2009
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Alexander Mayweg, Hans Peter Marty, Werner Mueller, Robert Narquizian, Werner Neidhart, Philippe Pflieger, Stephan Roever
  • Heterocyclic cannabinoid receptor antagonists
    Patent number: 7563910
    Abstract: The present invention relates to compounds of formula I and pharmaceutically acceptable salts thereof. The compounds are useful for the treatment and/or prophylaxis of diseases which are associated with the modulation of CB1 receptors.
    Type: Grant
    Filed: May 9, 2005
    Date of Patent: July 21, 2009
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Alexander Mayweg, Robert Narquizian, Philippe Pflieger, Stephan Roever
  • NEW 5-ARYL PYRIDINES AS 11-BETA INHIBITORS FOR THE TREATMENT OF DIABETES
    Publication number: 20090149503
    Abstract: Compounds of formula (I): as well as pharmaceutically acceptable salts and esters thereof used in the form of pharmaceutical compositions.
    Type: Application
    Filed: February 17, 2009
    Publication date: June 11, 2009
    Inventors: Kurt Amrein, Daniel Hunziker, Bernd Kuhn, Alexander Mayweg, Werner Neidhart
  • Indazolone derivatives useful as 11b-HSD1 inhibitors
    Patent number: 7528158
    Abstract: Compounds of formula (I) as well as pharmaceutically acceptable salts and esters thereof, wherein R1 to R7 have the significances given in the description and claims can be used in the form of pharmaceutical compositions.
    Type: Grant
    Filed: September 26, 2005
    Date of Patent: May 5, 2009
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Kurt Amrein, Jianping Cai, Robert Alan Goodnow, Jr., Daniel Hunziker, Bernd Kuhn, Alexander Mayweg, Werner Neidhart